PMID: 6401327Jan 1, 1983Paper

Auranofin in the treatment of juvenile rheumatoid arthritis

The Journal of Pediatrics
E H GianniniD A Person

Abstract

Auranofin (triethylphosphine gold) was administered to 21 patients with juvenile rheumatoid arthritis during an open-ended, open-label, noncontrolled trial designed to establish safety and preliminary efficacy. Initial dosage was 0.1 mg/kg/day; incremental increases to 0.2 mg/kg/day were allowed. Aspirin (80 mg/kg/day), tolmetin (20 to 40 mg/kg/day), and naproxen (400 to 600 mg/m2/day) were allowed as rapidly acting anti-inflammatory agents. All patients attained measurable plasma concentrations of gold during the study. Clinically significant improvement (greater than 25%) occurred in more than half the patients with regard to the number and severity of joints with swelling, pain on motion, and tenderness. The number of joints with active arthritis decreased by at least 25% in nine of the 19 patients. Group mean changes between the initial and final visit indicated improvement in all articular disease indices measured. Eleven of 16 patients with an elevated erythrocyte sedimentation rate showed decreases of at least 25%. The group given the higher dosage had a greater proportion of responders with decreases in erythrocyte sedimentation rate. Four of six patients whose sera contained rheumatoid factor showed decreases in its ti...Continue Reading

References

Nov 1, 1977·The Journal of Pediatrics·J E LevinsonJ Schaller
Apr 1, 1980·Arthritis and Rheumatism·E J BrewerE Barkley

❮ Previous
Next ❯

Citations

Jun 1, 1984·Primary Care·F P Alepa
Oct 1, 2008·World Journal of Pediatrics : WJP·Nicolino Ruperto, Alberto Martini
Aug 1, 1991·Baillière's Clinical Rheumatology·W F Kean
Dec 30, 1983·The American Journal of Medicine·E J BrewerD A Person
Aug 18, 2004·Current Opinion in Rheumatology·Nicolino Ruperto, Alberto Martini
Apr 3, 2008·Arthritis and Rheumatism·Nicolino RupertoUNKNOWN Pediatric Rheumatology Collaborative Study Group
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A M Prieur, P Quartier
May 8, 2002·Paediatric Drugs·Ian C Chikanza
Aug 1, 2020·Signal Transduction and Targeted Therapy·Lei YangFudi Wang
Jun 1, 1984·Clinical Rheumatology·O Garcia-MorteoS Abate

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.